TAMPA, Fla.--(BUSINESS WIRE)—May 2, 2005--Nanobac Life Sciences, Inc. (OTCBB:NNBP). ("Nanobac" or "the Company") informs that new research done at Cardiff University, UK with the University of Ulm, Germany shows that Nanobacteria in clouds might be responsible for spreading illnesses such as heart disease, kidney stones and HIV. A scientific research paper authored by Chandra Wickramasinghe, PhD (Professor at Cardiff University, UK) and Andrei Sommer, PhD (Professor at the University Of Ulm, Germany) was recently published in the Journal of Proteome Research. A summary article was additionally released in the Environment News Service Newswire April 11, 2005. The Article was entitled “Nanobacteria in Clouds may Spread Diseases around the World”.
Dr. Wickramasinghe, the scientist credited for discovering that dust in interstellar space and comets is largely organic, now says in his research article that Nanobacteria in clouds may provide one possible explanation as to how Nanobacteria are spread across the world. He also says that these Nanobacteria are widespread on land and in our atmosphere, and that they play a crucial role in diseases.
Co-researcher, Dr. Sommer, agrees that Nanobacteria are involved in the formation of kidney stones, heart disease, HIV and some cancers. “Experiments have shown that Nanobacteria are excreted from the body in urine and their disbursal from the ground into the atmosphere and stratosphere appears to be inevitable,” said Dr. Sommer.
In their research paper in the Journal of Proteome Research, Drs. Wickramasinghe and Sommer write “on the one hand, they (Nanobacteria) appear as primal biosystems originating life; on the other hand, they cause severe diseases.” Their work corroborates the findings of researcher Dr. Rupert Jaenicke (Maine, Germany) on bioaerosols and airborne contaminants. Dr Jaenicke’s work has been published in the Journals, New Scientist and Science.
Researchers from NASA-Houston have reported that Nanobacteria grow faster in a microgravity environment and this may explain why astronauts get kidney stones on space missions. The NASA research, published in Kidney International called for a major initiative to research Nanobacteria and disease.
Nanobacteria were discovered in 1988 and have been found in the centers of kidney stones, gall stones, coronary artery and vascular plaques, prostate stones, breast calcifications, ovarian cancer, dermatological diseases, Alzheimer’s disease and brain calcifications. Neva Ciftcioglu, PhD, the lead Nanobacteria researcher at NASA-Houston states: “Hopefully, eradication or treatments of these diseases will be possible in the near future.”
A popular book recently published by Douglas Mulhall entitled “The Calcium Bomb” describes in lay terms the discovery and science of Nanobacteria research and chronicles the key players and their landmark research. Mulhall’s book describes in great detail how Nanobacteria are involved in the development of many debilitating human diseases, how Nanobacteria can be medically detected and then treated with nanobiotics.
Landmark Nanobacterial research is currently being conducted in concert with Nanobac Life Sciences at the Mayo Clinic-Rochester under the direction of Drs. Franklin Cockerill, Virginia Miller and John Lieske; at NASA-Houston under the supervision of Neva Ciftcioglu, PhD, Director of Science at Nanobac and at the University of Kuopio, under the supervision of Olavi Kajander, Chief Research Officer at Nanobac. Additionally, studies have been completed at the Cleveland Clinic Florida by Daniel Shoskes, MD and at the Washington Hospital Medical Center Cardiovascular Institute with Stephen Epstein, MD.
The Chairman of Nanobac Life Sciences, John Stanton states, “We are very excited about the current intensity of Nanobacteria research being conducted, and about our product pipeline. We are very fortunate to be uniquely positioned to offer our patented Nanobacterial diagnostics and anti-nanobacterial nanobiotic treatments to the medical research community. We are looking forward to partnering with larger pharmaceutical companies so that we can expand the depth and breadth our research into Nanobacteria-related diseases as well as expand our product pipeline.”
Nanobac Life Sciences, Inc. is dedicated to improving human health through the detection and eradication of Nanobacteria related human diseases. The Company's pioneering research is further establishing the pathogenic roles of Nanobacteria in disease-related human calcification, particularly as it is involved in coronary artery heart disease process, vascular diseases, prostatitis, kidney diseases and cancer. Nanobac has identified and established two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop novel therapeutics to treat nanobacterial infections. The Company currently markets a patented nanobiotic regimen and has developed tests to detect Nanobacteria in blood, serum, tissues, urine and spinal fluids. Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our websites at: http://www.nanobaclifesciences.com or http://www.nanobacsciences.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.
Contact:
Nanobac Life Sciences, Inc, Tampa
John Stanton, Chairman & CEO or
Grant Carlson, President & COO.
Telephone: (813)264-2241 or Email: info@nanobaclifesciences.com